Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385609 | 0.96 | POLB (0.54) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| SCHEMBL2387108 | 0.94 | POLB (0.57) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| Water SCHEMBL27641336 | 0.94 | POLB (0.53) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| SCHEMBL16902846 | 0.93 | OPRM1 (0.52) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| SCHEMBL16902847 | 0.92 | OPRM1 (0.54) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| SCHEMBL9986991 | 0.92 | OPRM1 (0.54) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| Resorcinol SCHEMBL5982627 | 0.88 | POLB (0.48) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| SCHEMBL13806374 | 0.84 | HRH1 (0.62) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| SCHEMBL12760850 | 0.84 | OPRM1 (0.48) | OPRM1OPRK1KCNH2POLBCHRNB4 | |
| 3-Hydroxybenzaldehyde SCHEMBL6559274 | 0.83 | POLB (0.47) | OPRM1OPRK1KCNH2POLBKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011158149-A1 | 2-(3,5-DISUBSTITUTEDPHENYL)PYRIMIDIN-4(3H)-ONE DERIVATIVES | PFIZER INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-7060717-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| US-6949573-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1476158-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2004-11-11 | — | — | US | disclosed |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1363876-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Abbott Laboratories (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068233-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2002064550-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | OPRM1 4770/4885OPRK1 3998/4885KCNH2 3287/4885 |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | NNT, IL5, NOX5 | OPRM1 2501/4885OPRK1 763/4885KCNH2 743/4885 |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | OPRM1 4770/4885OPRK1 3998/4885KCNH2 3287/4885 |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | OPRM1 4770/4885OPRK1 3998/4885KCNH2 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.